Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 8Neoplasms 2Breast Neoplasms 2Urogenital Neoplasms 1Stage II Prostate Adenocarcinoma 1Prostate Adenocarcinoma 1Neoplasms by Site 1Genital Neoplasms, Male 1Genital Diseases, Male 1

Interventions

pembrolizumab 5padeliporfin 5Nivolumab 5fludarabine 4aldesleukin 4Ipilimumab 4Cyclophosphamide 4atezolizumab 3Sunitinib 3Specimen Handling 3Paclitaxel 3Mitomycin 3Magnetic Resonance Spectroscopy 3Gemcitabine 3Drug Therapy 3Carboplatin 3Biopsy 3Abiraterone Acetate 3vedolizumab 2olaparib 2niraparib 2motexafin gadolinium 2enfortumab vedotin 2darolutamide 2cabozantinib 2anlotinib 2abiraterone 2Therapeutics 2Suspensions 2Surveys and Questionnaires 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urogenital Neoplasms × BAY 86-7548 × Clear all
NCT02483884 2017-03-22

PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer

Lantheus Biosciences Ltd.

Phase 1/2 Terminated
30 enrolled
Genitourinary

Genital Diseases, Male, Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡